Xilio Therapeutics (XLO) Retained Earnings (2020 - 2026)

Xilio Therapeutics has disclosed Retained Earnings across 7 years of filings, most recently posting -$428.3 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$428.3 million, down 7.88% year-over-year; the trailing twelve-month figure through Mar 2026 was -$428.3 million (down 7.88% YoY), and the FY2025 annual result was -$418.8 million, down 9.13% from the prior year.
• Retained Earnings came in at -$428.3 million for Q1 2026 at Xilio Therapeutics, down from -$418.8 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$182.2 million in Q1 2022 to a low of -$429.1 million in Q3 2025.
• The 5-year median for Retained Earnings is -$342.7 million (2024), against an average of -$329.5 million.
• Across the five-year window, Retained Earnings plunged 60.53% in 2022 and dropped 7.88% in 2026, its largest moves.
• Xilio Therapeutics' Retained Earnings stood at -$249.1 million in 2022, then slumped by 30.67% to -$325.5 million in 2023, then fell by 17.89% to -$383.8 million in 2024, then fell by 9.13% to -$418.8 million in 2025, then dropped by 2.28% to -$428.3 million in 2026.
• The last three Retained Earnings figures came in at -$428.3 million (Q1 2026), -$418.8 million (Q4 2025), and -$429.1 million (Q3 2025), per Business Quant data.